000243130 001__ 243130
000243130 005__ 20230208174141.0
000243130 0247_ $$2CORDIS$$aG:(EU-Grant)957495$$d957495
000243130 0247_ $$2CORDIS$$aG:(EU-Call)ERC-2020-PoC$$dERC-2020-PoC
000243130 0247_ $$2originalID$$acorda__h2020::957495
000243130 035__ $$aG:(EU-Grant)957495
000243130 150__ $$aDevelopment of small molecule OGG1 Inhibitor and proof of concept in bleomycin-induced disease model of Inflammation and pulmonary Fibrosis$$y2020-11-01 - 2022-04-30
000243130 372__ $$aERC-2020-PoC$$s2020-11-01$$t2022-04-30
000243130 450__ $$aDOIIF$$wd$$y2020-11-01 - 2022-04-30
000243130 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000243130 680__ $$aFibrosis in response to tissue damage or persistent inflammation is a pathological hallmark of many chronic degenerative diseases where
Idiopathic Pulmonary Fibrosis (IPF) is one of the most severe diseases. IPF is a progressive condition with unknown etiology and a median
survival of three years from diagnosis. Current medical treatment is limited to slowing down the disease and thus there is still a high unmet medical need. OGG1 enzyme has a major role in DNA repair in conditions of oxidative stress and also in regulation of gene transcription involved in immune responses. In our ERC grant we developed a first-in class OGG1 inhibitor that protects from exaggerated immune response induced by the proinflammatory mediator TNFα. We have shown with this compound in
several airway inflammation models, that inhibition of OGG1 results in a significant down regulation of mediators associated with inflammation and fibrosis, reduced infiltration of immune cells in lungs and increased alveolar integrity compared with control. We have developed a large number of compounds and in this proposal we aim to demonstrate proof of concept (PoC) for the most promising compound in an established model of pulmonary fibrotic diseases in order to select a candidate drug (CD). Our plan is to establish collaboration with industrial partners for further development in order take one compound through preclinical development and clinical phase 1/2a for further commercialization. Treatment with a potent OGG1 inhibitor has the potential to attenuate or resolve the progress of the disease, alone or in combination with existing therapies and increase survival of IPF patients and reduce healthcare costs.
000243130 909CO $$ooai:juser.fz-juelich.de:899570$$pauthority$$pauthority:GRANT
000243130 909CO $$ooai:juser.fz-juelich.de:899570
000243130 980__ $$aG
000243130 980__ $$aCORDIS
000243130 980__ $$aAUTHORITY